What We Do

Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead product candidate is bertilimumab, a first-in-class, fully human, anti-eotaxin-1 antibody, which has completed phase 2 trials in bullous pemphigoid, allergic rhinitis and allergic conjunctivitis, and is in an ongoing phase 2 trial in ulcerative colitis. We intend to move bertilimumab into a pivotal phase 2/3 study in bullous pemphigoid, expected to launch in 2019.  Bertilimumab may have application in other diseases, including asthma, atopic dermatitis and other inflammatory disorders.

Our pain portfolio includes AmiKet, a phase 3-ready topical analgesic cream containing amitriptyline and ketamine for the treatment of peripheral neuropathies including postherpetic neuralgia and diabetic neuropathy, and AmiKet Nano, a nano-encapsulated formulation of AmiKet. AmiKet's comprehensive phase 2 program demonstrated significant pain reduction in postherpetic neuralgia and clinically meaningful activity in diabetic perhipheral neuropathy.  We are actively seeking to partner or divest the AmiKet program.

Our oncology portfolio includes Ceplene® (histamine dihydrochloride), an immunostimulant that is approved for use in over 30 countries for the maintenance of first remission in patients with acute myeloid leukemia (AML). Ceplene is administered in conjunction with low-dose IL-2 for enhanced anti-tumor immunity. A phase 3 trial in 320 AML patients showed that the combination of Ceplene and low-dose IL-2 improved the relapse rate while maintaining good quality of life during treatment.  Additional oncology programs include Azixa and crolibulin, two clinical stage vascular disrupting agents.  We are actively seeking to divest our oncology programs.

Other

Bertilimumab

Bullous Pemphigoid

Preclinical Phase 1 Phase 2 Phase 3
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Bertilimumab

Ulcerative Colitis

Preclinical Phase 1 Phase 2 Phase 3
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Bertilimumab

Allergic Rhinitis

Preclinical Phase 1 Phase 2 Phase 3
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Bertilimumab

Allergic Conjunctivitis

Preclinical Phase 1 Phase 2 Phase 3
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

NanoCyclo

Atopic Dermatitis/Psoriasis

Preclinical Phase 1 Phase 2 Phase 3
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started